Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency 
Nanya Technology Shares Surge 10% After $2.5 Billion Private Placement from Sandisk and Cisco 
SK Hynix Eyes Up to $14 Billion U.S. IPO to Fund AI Chip Expansion 
Explosion and Fire Erupt at Valero Oil Refinery in Port Arthur, Texas 
OpenAI Pulls the Plug on Sora, Ending $1 Billion Disney Partnership 
SpaceX IPO Filing Expected This Week as Valuation Could Surpass $75 Billion 
Asian Currencies Stay Muted as Dollar Holds Firm Amid Iran Uncertainty 
Wall Street Slides as Iran War Uncertainty, Oil Surge, and AI Fears Rattle Markets 
Berkshire Hathaway and Tokio Marine Form Major Strategic Insurance Partnership 
Currency Markets Show Caution Amid U.S.-Iran Negotiations 
Trump Tariffs Show Minimal Economic Impact but Boost Federal Revenue, Study Finds 
Bank of Japan Officials Signal Continued Interest Rate Hikes Amid Inflation Concerns 
Gold Prices Climb as Middle East Ceasefire Talks Stir Market Optimism 
Oil Prices Plunge Over 6% as Middle East Ceasefire Hopes Ease Supply Fears 
Gold is meant to be a ‘safe haven’ in uncertain times. Why is it crashing amid a war? 
Golden Dome Missile Defense: Anduril and Palantir Join Forces on Trump's $185B Space Shield 
Australia-EU Free Trade Deal Signed After Years of Negotiations 
Samsung Biologics signed a new deal with GSK, formerly GlaxoSmithKline. This will be their second manufacturing deal, and this time the agreement value is $296.1 million.
The amount is said to be almost 30% of the full-year revenue of Samsung last year, which was KRW1.5 trillion or around $1 billion, and the contract with GSK is in effect until the end of 2030. Samsung Biologics is currently the top Contract Manufacturing Organization in the world in terms of capacity, and its latest deal with the said British pharmaceutical industry company is for the supply of biopharma products.
Samsung Biologics and GSK plc confirmed their second collaborative contract late last week. As per The Korea Economic Daily, the biotech unit of the Samsung Group did not disclose the details of the exact products it will make for GSK under their contract.
One of their earlier deals was signed in May 2020, and it was a contract worth $231 million. It was also for the supply of biopharma products for eight years since the contract was made official. To be more specific, this was for the production and delivery of GSK’s Benlysta (belimumab) drug, which is used for the treatment of the autoimmune disease - lupus nephritis.
GSK and Samsung Biologics expanded their deal and signed another contract in August 2020, which was worth $368.1 million. It was a CMO agreement to produce sotrovimab, a SARS-CoV-2 monoclonal antibody that targets the COVID-19 virus.
In any case, the new deal is a remarkable expansion of the business relationship between Samsung Biologics and GSK. They already partnered in several projects, and now larger contracts are coming up
Meanwhile, Fierce Pharma reported that the new agreement comes as Samsung Biologics launches its “Super Plant,” which is also its fourth manufacturing facility. It sits in the company’s huge complex in Incheon, South Korea. It has invested more than $2 billion in the construction of this massive plant as part of its ambitious plan to become a major global player in the contract development and manufacturing organization scene.
